Lin Wen

554 total citations
15 papers, 74 citations indexed

About

Lin Wen is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Lin Wen has authored 15 papers receiving a total of 74 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Epidemiology. Recurrent topics in Lin Wen's work include Silymarin and Mushroom Poisoning (3 papers), Liver physiology and pathology (2 papers) and Liver Disease Diagnosis and Treatment (2 papers). Lin Wen is often cited by papers focused on Silymarin and Mushroom Poisoning (3 papers), Liver physiology and pathology (2 papers) and Liver Disease Diagnosis and Treatment (2 papers). Lin Wen collaborates with scholars based in China, Germany and United Kingdom. Lin Wen's co-authors include Xiaofang Li, Xiaolian Liu, Xinyu Zhao, Yuhao Zheng, Xuliang Huang, Junlu Wang, Anqi Zhang, Yunchang Mo, Qingqing Huang and Fan Xie and has published in prestigious journals such as International Journal of Pharmaceutics, International Journal of Biological Macromolecules and Journal of Neuroinflammation.

In The Last Decade

Lin Wen

11 papers receiving 74 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lin Wen China 5 36 17 14 12 11 15 74
Yong Bi China 7 43 1.2× 20 1.2× 21 1.5× 11 0.9× 7 0.6× 11 107
Min Qiao China 5 44 1.2× 8 0.5× 23 1.6× 4 0.3× 7 0.6× 6 101
Dingguo Huang Hong Kong 5 42 1.2× 12 0.7× 10 0.7× 10 0.8× 3 0.3× 14 132
Poppy Iveson United Kingdom 4 62 1.7× 39 2.3× 21 1.5× 5 0.4× 6 0.5× 5 135
C. Y. Yang China 8 44 1.2× 26 1.5× 16 1.1× 3 0.3× 5 0.5× 15 124
Davide Luppi Italy 3 28 0.8× 32 1.9× 7 0.5× 4 0.3× 11 1.0× 4 85
James E. B. Curson Australia 7 62 1.7× 74 4.4× 19 1.4× 12 1.0× 4 0.4× 11 148
Marina Degoricija Croatia 8 71 2.0× 30 1.8× 11 0.8× 3 0.3× 8 0.7× 12 154
Pengyi Yan China 5 60 1.7× 13 0.8× 13 0.9× 4 0.3× 5 0.5× 12 117
Agustín Pérez-Londoño Colombia 3 38 1.1× 10 0.6× 12 0.9× 5 0.4× 4 0.4× 5 85

Countries citing papers authored by Lin Wen

Since Specialization
Citations

This map shows the geographic impact of Lin Wen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Wen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Wen more than expected).

Fields of papers citing papers by Lin Wen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lin Wen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Wen. The network helps show where Lin Wen may publish in the future.

Co-authorship network of co-authors of Lin Wen

This figure shows the co-authorship network connecting the top 25 collaborators of Lin Wen. A scholar is included among the top collaborators of Lin Wen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lin Wen. Lin Wen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Wen, Lin, et al.. (2025). Nanoparticle: Pathogenesis, Innovative Diagnosis, and Therapy of Liver Fibrosis. ChemistrySelect. 10(7). 1 indexed citations
2.
3.
4.
Wen, Lin, et al.. (2025). Oral delivery of Silybin via HA-DOCA-functionalized zein nanocolloids for amelioration of liver fibrosis. International Journal of Biological Macromolecules. 334(Pt 1). 149042–149042.
5.
Liu, Xing, et al.. (2025). Peroxidase modification-driven silymarin liposomes for the treatment of liver fibrosis. Nanomedicine Nanotechnology Biology and Medicine. 69. 102851–102851. 1 indexed citations
6.
Wen, Lin, et al.. (2024). Silybin: A Review of Its Targeted and Novel Agents for Treating Liver Diseases Based on Pathogenesis. Phytotherapy Research. 38(12). 5713–5740. 14 indexed citations
7.
Liu, Kai, et al.. (2024). Diosmetin as a promising natural therapeutic agent: In vivo, in vitro mechanisms, and clinical studies. Phytotherapy Research. 38(7). 3660–3694. 14 indexed citations
8.
Huang, Xuliang, Yuhao Zheng, Nan Wang, et al.. (2024). Dichloroacetate Prevents Sepsis Associated Encephalopathy by Inhibiting Microglia Pyroptosis through PDK4/NLRP3. Inflammation. 48(3). 1159–1175. 6 indexed citations
9.
Wen, Lin, et al.. (2024). Data Driven Solution to Market Equilibrium via Deep Reinforcement Learning. 1422–1426. 1 indexed citations
10.
Liu, Xing, et al.. (2024). Lipid nanosystems for fatty liver therapy and targeted medication delivery: a comprehensive review. International Journal of Pharmaceutics. 669. 125048–125048. 1 indexed citations
11.
Zhang, Anqi, et al.. (2024). Identification and verification of disulfidptosis-related genes in sepsis-induced acute lung injury. Frontiers in Medicine. 11. 1430252–1430252. 3 indexed citations
12.
Xuan, Lina, Zhenxin Hu, Cong Zhang, et al.. (2023). Pregnane X receptor (PXR) deficiency protects against spinal cord injury by activating NRF2/HO‐1 pathway. CNS Neuroscience & Therapeutics. 29(11). 3460–3478. 6 indexed citations
13.
14.
Huang, Xuliang, Xinyu Zhao, Lin Wen, et al.. (2023). TRIM45 aggravates microglia pyroptosis via Atg5/NLRP3 axis in septic encephalopathy. Journal of Neuroinflammation. 20(1). 284–284. 25 indexed citations
15.
Wen, Lin, et al.. (2003). M-ary MC CDMA in uplink for next generation mobile communication. 3. 2526–2530 Vol.4. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yong Bi Breakdown of academic impact, for papers by Min Qiao Breakdown of academic impact, for papers by Dingguo Huang Breakdown of academic impact, for papers by Poppy Iveson Breakdown of academic impact, for papers by C. Y. Yang Breakdown of academic impact, for papers by Davide Luppi Breakdown of academic impact, for papers by James E. B. Curson Breakdown of academic impact, for papers by Marina Degoricija Breakdown of academic impact, for papers by Pengyi Yan Breakdown of academic impact, for papers by Agustín Pérez-Londoño
Rankless by CCL
2026